

January 15, 2019

MYOS RENS Technology Announces Study Results Demonstrating Fortetropin®, the Active Ingredient in Myos Canine Muscle Formula, Prevents Muscle Loss in Canines After Surgery and Enhances Recovery

Positive Results Obtained from Kansas State University Study

Company to Host Update Conference Call Today at 11:00 a.m. ET to Discuss Results

CEDAR KNOLLS, N.J., Jan. 15, 2019 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (NASDAQ: MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle, **announced today positive top-line results** from a randomized, double-blind, placebo-controlled study by Kansas State University evaluating the impact of Fortetropin on attenuating muscle atrophy following a common surgical procedure known as tibial-plateau leveling osteotomy ("TPLO") in 100 dogs.



In the weeks that follow TPLO surgery, immobilization of the dog's limb is required and the operated limb frequently shows significant muscle loss due to muscle disuse atrophy. The objective of the study, which was sponsored by the Company, was to determine whether Fortetropin could reduce this muscle atrophy.

Key findings of the study:

- Fortetropin prevented the loss of muscle mass in these dogs as measured by the thigh circumference in their affected and unaffected limbs.
- Fortetropin-supplemented dogs had a more significant improvement in percentage of weight supported by the affected limb as determined by force plate stance analysis (more rapid return to normal stance force distribution) than the placebo group.
- Fortetropin prevented a rise in serum myostatin levels. Myostatin is a protein that

prevents muscle growth.

Kenneth R. Harkin, DVM, DACVIM (SAIM), Professor and Section Head, College of Veterinary Medicine, Kansas State University, and principal investigator of the study commented, "This study demonstrates the benefits of Fortetropin in dogs with prolonged post-operative recovery periods. Restoration or maintenance of muscle mass through the reduction of serum myostatin levels with Fortetropin offers veterinarians a novel approach to in-home rehabilitation of injured dogs, including potentially improving or restoring mobility in geriatric dogs."

Joseph Mannello, CEO of MYOS, commented, "We believe the results of this study will be transformative for MYOS. First, we expect the study results will enable us to expand our veterinary business with a product that is truly disruptive and can change the way pet owners and veterinarians address canine muscle health. Second, the study results reinforce our plans to pursue clinical trials for human rehabilitation and recovery. These areas of tremendous market potential will be discussed further during our conference call later, today."

Professor Harkin will present an oral summary of study results on **January 20, 2019 at the North American Veterinary Community (NAVC) / VMX Conference** (<https://navc.com/vmx/>) in Orlando, Florida. The presentation will be entitled, "***The Impact of Fortetropin[®] Supplementation on Dogs Recovering from Tibial-Plateau Leveling Osteotomy (TPLO) Surgery***" and will be presented in the Discovery Theater at the **VMX Conference at 3:15 pm.**

Conference Call Details:

Call Date/Time: Tuesday, January 15, 2019 at 11:00 am ET

Call Title: MYOS RENS Technology Business Update Conference Call

Dial In: 877-407-4019 from the U.S.; international callers may telephone 201-689-8337, approximately 10 minutes before the call.

A digital replay will be available by telephone approximately two hours after the completion of the call until April 15, 2019 and may be accessed by dialing 877-660-6853 from the U.S. or 201-612-7415 for international callers, using the Conference ID# 13686568.

This call will be simultaneously webcast. The webcast will be available on the MYOS website, www.myosrens.com, in the "Investor Relations" section. The webcast will be archived and available at the same web address for two weeks following the call.

About MYOS RENS Technology Inc.

MYOS RENS Technology Inc. (MYOS), "The Muscle Company[®]", is a Cedar Knolls, NJ-based bionutrition company that develops and markets products that improve muscle health and performance. MYOS is the owner of Fortetropin[®], a fertilized egg yolk-based product manufactured via a proprietary process to retain and optimize its biological activity. Fortetropin has been clinically shown to increase muscle size and lean body mass in conjunction with resistance training. MYOS believes Fortetropin has the potential to

redefine existing standards of physical health and wellness. For more information, please visit www.MYOSRENS.com.

Forward-Looking Statements

*Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the ability to create new products through research and development, the successful results of strategic initiatives, the successful launch of our products, including **Qurr**[®], **Yolked**[®], **MYOS Enteral Nutrition Formula**[™] and **MYOS Canine Muscle Formula**[™] products, the success of our research and development, the results of the clinical evaluation of **Fortetropin**[®] and its effects, the ability to enter into new partnership opportunities and the success of our existing partnerships, the ability to generate the forecasted revenue stream and cash flow from sales of our products, the ability to continue increasing our revenue and gross profit margins, the ability to achieve a sustainable, profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, competition from other providers and products, the continued listing of our securities on the Nasdaq Stock Market, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in our filings with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.*

These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure or prevent any disease.

Investor Relations:

Porter LeVay & Rose

Michael Porter, President

Phone: 212-564-4700

Email: MYOS@plrinvest.com

 View original content to download multimedia <http://www.prnewswire.com/news-releases/myos-rens-technology-announces-study-results-demonstrating-fortetropin-the-active-ingredient-in-myos-canine-muscle-formula-prevents-muscle-loss-in-canines-after-surgery-and-enhances-recovery-300777991.html>

SOURCE MYOS RENS Technology